ADMA Biologics Inc. (NASDAQ:ADMA) fell 7% after it announced the US FDA had approved VanRX SA25, its in-house aseptic fill-finish machine. According to the company, with the machine operational, it expects significant improvement in gross margins, enhanced inventory-production-cycle times, improved patient supply consistency, and increased visibility and control of commercial-product-lot launches that will create predictable revenue results in the near term.
VanRx utilizes a closed isolator design that allows human interventions removal and offers safe drugs for patients. Most importantly, the machine can quickly change between various closure formats and containers to allow aseptic filling at different presentation sizes and fill volumes.
The company will continue working with a third-party CMO fill-finish partner that will continue filling a portion of its production at their location. The contract manufacturing organization’s facility remains the company’s FDA product BLA to offer alternatives and ensure there is a robust supply chain. Therefore, ADMA is worth keeping an eye on in the coming weeks.
On Wednesday, ADMA stock moved down 7.10% at $1.18 with more than 50.65 million shares, compared to its average volume of 2.33 million shares. The stock has moved within a range of $1.1700 – 1.4100 after opening the trade at $1.40.